Market revenue in 2023 | USD 2,781.9 million |
Market revenue in 2030 | USD 5,477.1 million |
Growth rate | 10.2% (CAGR from 2023 to 2030) |
Largest segment | Transdermal patches |
Fastest growing segment | Drug Eluting Stents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Photodynamic Therapy Devices, Transdermal Patches, Wound Care Products, Infusion Pumps, Orthopedic Combination Products, Drug Eluting Stents, Inhalers, Antimicrobial Catheters |
Key market players worldwide | Abbott Laboratories, Terumo Corp, Stryker Corp, Viatris Inc, Medtronic PLC, Boston Scientific Corp, Novartis AG ADR, Becton Dickinson & Co, Teleflex Inc, W L Gore & Associates |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to drug device combination products market will help companies and investors design strategic landscapes.
Transdermal patches was the largest segment with a revenue share of 22.9% in 2023. Horizon Databook has segmented the Sweden drug device combination products market based on photodynamic therapy devices, transdermal patches, wound care products, infusion pumps, orthopedic combination products, drug eluting stents, inhalers, antimicrobial catheters covering the revenue growth of each sub-segment from 2018 to 2030.
Sweden’s healthcare system prioritizes patient-centered care, propelling the adoption of drug-device combination products due to their user-friendly nature, enhanced patient adherence & treatment effectiveness. These advancements significantly enhance the efficacy & comfort of drug device combination products, ensuring better performance and improved patient experiences during medication administration.
Moreover, Sweden’s strong interest in adopting innovative medical technologies and its focus on progressive healthcare solutions is expected to improve the demand for state-of-the-art drug-device combination products. Furthermore, the country’s strict adherence to the European MDR, which prioritizes robust clinical evidence and cost-effectiveness, encourages the adoption of the most efficient & effective solutions.
In addition, initiatives undertaken by government and nongovernment bodies to promote the adoption of drug-device combination products are projected to fuel market growth over the forecast period.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden drug device combination products market , including forecasts for subscribers. This country databook contains high-level insights into Sweden drug device combination products market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account